Navigation Links
Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

Long-term benefits of preventing heart attacks highlighted in new study

presented at global health outcomes meeting

ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial progress in the diagnosis and treatment of heart attack patients, prevention of recurrent heart attacks continues to be a major clinical challenge. A new study showed that patients who suffered a non-fatal heart attack within the first three months of hospitalization for chest pain had a significantly higher risk for dying or having another heart attack (in the following three months to four years) compared with patients who did not experience a heart attack during the same initial period. The findings from the more-than-15,000- patient study were presented today at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 8-11.

In the study, patients who suffered a heart attack during the first three months after hospital admission for coronary artery disease compared with those who did not experience a heart attack during the same period were 62 percent (p<0.001) more likely to die and 84 percent (p<0.001) more likely to have an additional heart attack or death within four years. The increased rate of heart attack and death among patients who had a heart attack remained similar even when the monitoring was extended from a three-to-six month period. The researchers found that patients who suffered a heart attack within the six month period were 61 percent (p<0.001) more likely to die, and 86 percent (p<0.001) were more likely to suffer a recurrent heart attack or death over a four-year period compared with those who did not experience a heart attack.

"This study illustrated that heart attack patients may still suffer severe, life-threatening events over the next several years, even if they appear well," said study investigator David F. Kong, M.D., assistant professor of medicine, Division of Cardiovascular Medicine, Duke University Medical Center & Duke Clinical Research Institute, Durham, N.C., USA. "Surviving an initial heart attack does not mean that a patient is 'out of the woods'. Earlier diagnosis and interventions to help prevent heart attacks could improve long-term outcomes for patients."

About the Study

The study analyzed 15,604 patients with significant coronary heart disease undergoing diagnostic catheterization, a procedure in which a thin plastic tube is inserted into an artery to take pictures of the blood vessels that supply the heart. Patients were classified as having a non-fatal heart attack within three months of their first catheterization in a hospital or as being event-free within the three-month period. The median follow-up time for both groups was 4.2 years.

In the retrospective analysis, patients in the heart attack vs. no heart attack group were similar in age (median of 62 vs. 63), female sex (36 percent vs. 33 percent), history of hypertension (69 percent vs. 68 percent), history of diabetes (36 percent vs. 30 percent) and multi-vessel coronary artery disease (61 percent vs. 58 percent). The median follow-up time for both groups was 4.2 years.

The study was conducted at Duke Clinical Research Institute, part of Duke University Medical Center, by Eric Eisenstein, D.B.A., Patricia Cowper, Ph.D., David Kong, M.D., and Kevin Anstrom, Ph.D., with support from the Health Outcomes groups at Daiichi Sankyo and Lilly.

About Coronary Heart Disease

As one of the primary forms of cardiovascular disease, coronary heart disease occurs when the coronary arteries become narrowed or clogged by cholesterol and fat deposits inside the arteries through a process called atherosclerosis. Heart attacks are a major manifestation of coronary heart disease, which constitutes an enormous health burden throughout the world. Annually, 3.8 million men and 3.4 million women worldwide die from coronary heart disease.(1) The rates of death in coronary heart disease patients are particularly high. Of all patients who die within 28 days after the onset of symptoms, approximately two-thirds die before reaching the hospital.(2) Long- term prevention of heart attacks and further cardiac events in patients who already experienced a non-fatal heart attack is crucial to improve the lives of coronary heart disease patients.

About Daiichi Sankyo

A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.


(1) World Health Organization. The Atlas of Heart Disease and Stroke - Deaths from Coronary Heart Disease. 2005.

(2) World Health Organization. The Atlas of Heart Disease and Stroke - Deaths from Coronary Heart Disease. World Health Organization, 2005.

(Logo: )

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
(Date:11/30/2015)... Fla. , Nov. 30, 2015   The ... (the Institute) announced today that it has finalized a ... start-up company with technology developed at Florida State University. ... research, and bridges early funding gaps for companies spinning ... research institutions. --> ...
(Date:11/30/2015)... , November 30, 2015 /PRNewswire/ ... --> adds a ... for 2010 - 2015 with comprehensive ... a range of deal types, such ... strategic alliances. ...
(Date:11/30/2015)... -- --> --> According ... Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative ... - Global Forecast to 2020", published by MarketsandMarkets, is expected ... of 5.2% during the forecast period from 2015 to 2020. ... Figures spread through 167 P ages and in-depth TOC ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Tympani Inc., announced today that it ... Cisco. This designation recognizes Tympani as having fulfilled the training requirements and program ... the high-end enterprise contact center marketplace. , Ed Kapelinski, President of Tympani stated, ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of ... into its VIP Woman of the Year Circle. She is recognized with this ... exclusively for professional women, boasting 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... stressful. At the VA Maryland Health Care System, the Caregiver Support Program ... “Caregivers have a difficult job. Seventy-four percent report that their role as ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... dermatology, is proud to announce that its ThermiRFR temperature controlled radiofrequency platform has ... an innovative multi-application radiofrequency platform which uses temperature as a clinical endpoint. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... fun atmosphere for Halloween festivities, the Word of Life Christian Church of Flint, ... game, and featuring a giant 1.25 ton pile of candy dubbed “Candy Mountain”. ...
Breaking Medicine News(10 mins):